# Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy

> **NCT02780687** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 42 (actual)

## Conditions studied

- Urologic Neoplasms

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02780687
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-09
- **Primary completion:** 2018-09-24
- **Final completion:** 2019-09-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780687, "Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02780687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*